Internal accountability note, prepared October 13 on the October 12 settled screen (desk date = SPY's October 12 close; the week's baseline is the October 9 settled close). This is the Loop 4 companion to the Monday flagship and the one place the desk reads its own books, so paper ledgers, paper session logs and the desk's decision and call records are cited below. The real-money accounts were not read, and the screen's held class, which is drawn from them, was not unpacked. Nothing was fetched or backtested. Prices and returns are fields the engine computed in the desk's summaries (October 12 settled close unless dated) or figures printed by the week's briefs, scans, target reviews, call ledger and paper ledgers; none was computed by hand. Tuesday's session has not closed, so nothing dated October 13 is price truth.

FIRED triggers are pushed to the user: the October 12 trigger check printed ten FIRED rows, and none is actionable as written. Two sit on bench campaigns: the biotech campaign's CERT convert clause fired without its arm clause or its ratification gate, and the energy-disruption campaign's USO-above-$110 level has stood for more than 21 sessions. The other eight sit on closed campaigns, which are history under the date rule; none reopens on its old trigger. Readings are under "Trigger check".

The short version

• The screen: 1,263 symbols; 23 movers at +30% or more over 30 days with $10 million or more of daily dollar volume (four stale movers skipped). Four are covered and 19 are not: two own-or-decline clusters (security software, 3; biotech tools, 5) and an 11-name tail. 14 of the 19 were on the October 5 screen.
• It is not a coverage miss. All 19 sit on watchlists. 16 were named in a brief, scan, target review or nightly desk read during the week; NTSK, LIND and IMOS appeared only on the momentum boards.
• The decision step failed for a second week. The October 5 note asked for one grouped own-or-decline pass. Nothing is on file: no decision row on any of the 19 since October 5, no change to the biotech or optics campaigns' claimed names, no new entry in the biotech campaign log. The unwritten declines now generate work: the commissioning board routes PACB, NAUT and QSI to company deep dives.
• SDGR is inside its zone. The September 23 target ($23–$26, stop $20.50) printed in zone at $25.91 on October 12. SDGR shows as unclaimed only because its README anchor is missing from the campaign's registry row, the gap named on October 5.
• Security software was passed by rule twice. Okta as "extended"; Zscaler as "a bottom-and-pop, the long trend is not yet rebuilt", although its own target condition (a lighter-volume retest of $188–$198) printed on October 2. Cybersecurity is the month's strongest lane on the rotation map and has no campaign.
• Called right: the optics passes (AXT, MaxLinear and Semtech fell 12.73% to 28.48% over the seven days to October 12, two of three long trends intact); biotech's "a price bid is not the order evidence"; Nebius over CoreWeave; rates, not credit. Wrong or lapsed: Okta's July pass closed its 90-day window 44.47 points ahead of SPY; AXT's pass (+35.30 at 90 days) is still unreviewed twelve days past its review date; 53 of 80 open desk calls are past review.
• The books did not chase. Eleven Tier B books held Friday sessions and none bought. The week's fills were exits on written lines (Schlumberger, Bunge, Nutrien) and one photonics basket ticket that failed in three sessions. degen passed five straight index ENTERs for want of a thesis; on October 9 the coordinator adopted Evolved Rule 2 under the user's delegation, and TQQQ and SPXL are parked for today's noon fill.

What the screen says

miss-screen, October 12 settled close. MISS means no book holds the symbol and no active or monitoring campaign lists it among its claimed names; alone it does not show a missed notice, a passed entry or an executable T−1 trigger. Each row answers the operating book's three questions: in our data? which thesis should own it? what trigger at T−1? "(signal row)" marks a generated brief line, not desk prose. The four covered movers are not named in the screen's text output and are not unpacked here, because the held class reads the real-money ledgers.

The screen shrank from 41 movers on October 5 to 23. The October 5 optics cluster (14 names) is gone: every US-listed name in it except Everpure now shows a 30-day gain under 30%, after the AI-hardware selling of October 8 and October 12 recorded in the Friday and Monday briefs. The screen does not print its four stale-skipped movers; four rows fit, the Asian listings whose last bars are dated October 8–9 (6920.T, 3037.TW, 3105.TWO, 8046.TW, each above +30% over 30 days on those bars). None has normal trade access on record.

The prior-verdict join worked: the screen printed the October 5 note's single-line verdict ("OPEN; BOTH CLUSTERS PASSED BY RULE, OWN-OR-DECLINE OWED") against the biotech cluster with five repeats. The parser defect (a folded verdict reads as >-) is still an open engine row; the single-line verdict is the workaround.

Cluster 1 — security software, labeled "nvidia-open-agent-ecosystem" (3 MISS, $1,378M aggregate dollar volume; first clustered appearance)

The label is a watchlist built on September 30 from one X post (Lin, @Speculator_io, September 28) naming companies in NVIDIA's open-agent ecosystem; its own description calls the association "a research lead". The real neighborhood is the cybersecurity list, which the rotation map ranks the month's strongest lane: relative strength +21.8 on October 9 and +20.3 on October 12, every name in a strong uptrend.

Zscaler. The watch call's condition was met on closes on September 29 ($198.36) and flagged in zone September 30. On October 2 the target's requested shape printed: a $196.60 close inside the band on 0.46 times normal volume. That night's target review kept the level and declined the entry as "a reversal off a broken long trend, not an intact one", the year then −36.1% with alpha −51.1, and the nightly desk read repeated it through October 12 ("Chasing the gap" at $225.78). Zscaler closed the week at $233.73 (October 9 cybersecurity scan); the call ledger's return since the September 25 call is +16.95%. Two filed 8-Ks went unread: September 24 (named in the September 25 target review) and October 6 (captured, body unread). Cause of the move: unknown. The October 8 news pull held quote pages and Friday's +7.8% came after it (cybersecurity scan); the October 12 pull holds quote, financials and September earnings pages; stock-events and the October 5–12 captures carry nothing.

Okta. The July 8 pass closed its 90-day window this week at +44.47 points over SPY (raw +48.99, call ledger), after grading as a good pass at 30 days (−2.68). Okta closed at $232.13 on October 9, 0.36% under its high (tech-insider scan). Cause: unknown. News was last pulled October 3 at Friday's scan; the October 9 pull holds price-target and quote pages; stock-events and captures carry nothing beyond an October 9 Form 4.

Disposition. A conviction miss by rule, not coverage, and two rules did the passing. Okta went as extended. Zscaler went on the long-trend rule the desk is told to apply: down on the year with negative alpha is the broken name. But Zscaler's path is also the user's stated entry pattern, bottom → pop → flag → breakout. The Lazarus screen had it waking at 4 of 5 on October 5 and 9; the September breakout was the pop, the October 2 light-volume retest the flag, the run to $233.73 the breakout. The rule and the pattern disagree on exactly this kind of repair name, and only the user can say which governs. The structural gap is upstream: the month's strongest lane has no campaign, so every read ends at "extended" with nothing to own the name.

Cluster 2 — biotech tools (5 MISS, $579M aggregate dollar volume; owed since October 5, all five repeats)

Over the 30 days to October 12, IBB is +0.66% and XBI −3.07% (desk summaries), and the rotation map lists the capital-cycle lane among the fading leaders. This is still a small and mid-cap tools run inside a soft sector. TXG left the screen: the October 6 genomics unwind (1 of 36 up; TXG −17.47%, cause unknown per that day's brief) cut its 30-day gain to 9.62%.

Disposition. A conviction miss by rule plus registry drift, owed since October 5. Three things changed:

1. SDGR became actionable on its own written terms, inside the September 23 zone on an intact long trend. A yes/no is owed now.
2. The July 26 mid-cap rule is near its arm, and its gate has moved away. The rule arms on a pullback reset (TXG or CERT RSI under 45) and converts on the resume (RSI back over 55, price over the 20-day), but only "with the ratification gate confirming" (TMO, DHR and MEDP all over RSI 60). TXG prints ARMED at RSI 47.3, its arm in reach for the first time since July. The gate went the other way: TMO stood at RSI 64.7 in the campaign's October 5 table, and all three now sit in the mid-50s. As written, a TXG arm this week is still not an entry.
3. CERT printed FIRED on the convert clause alone, with the arm DORMANT at the print and the gate unmet, so the line means nothing under the rule. Whether CERT dipped under 45 between October 5 (RSI 75 on the momentum board) and the cross cannot be read from a screen that evaluates clauses one at a time: the open sequential-clause engine row, now on a second symbol.

The suppliers that decide the campaign are scheduled to report around October 21 (Medpace, Danaher, Thermo Fisher, ICON, per Friday's campaign dispatch).

The unclustered tail (11)

Six of the 19 carry the stretch screen's exhaustion class at the October 12 close (extended, rising on below-average volume): P, NTSK, IOVA, KOD, BWET and LIND. The stretch passes are consistent with the tape.

Trigger check — FIRED and ARMED (October 12 close)

The check watches nothing on the book. Of the six active campaigns, five carry watch-for text with no clause the check can parse, and energy-to-humanitarian-transmission carries no watch-for field at all, so it is absent from the check. Every evaluable row sits on a bench or closed campaign.

What the desk called right and wrong

Right:

• The optics passes. On October 5 the extended component names were "buy flags, not gaps", and that night's autopsy proposed owning MaxLinear, Semtech, AXT and Viavi. Nothing was bought. Over the seven days to October 12 AXT fell 28.48%, MaxLinear 15.64% and Semtech 12.73% (desk summaries). MaxLinear (58.6% above its 200-day on a +464.66% year) and Semtech (39.8% above on +146.49%) are deep pullbacks in intact trends; AXT, 0.3% under its 200-day on a +1,247.39% year, is a long trend under test.
• Biotech. "A price bid is not the order evidence the biotech-funding case asks for" (October 5). The capital-cycle lane went 1 of 36 up the next day.
• Neoclouds by the long window. The October 5 CoreWeave deep dive said stand aside below $85.64; CoreWeave closed at $82.08 on October 9, 11.3% under its 200-day. Nebius held 28.9% above its 200-day through Friday; Monday's close under the $219.70 shelf is still a deep pullback in an intact trend.
• Rates, not credit. High-yield spread 3.15% (October 8), VIX 14.84 (October 9), none of the twelve climate rows fired.
• The July pass cohort at 90 days. Five of seven July 8–9 passes trailed SPY (name minus SPY, points): ORCL −3.85, CIFR −33.58, CORZ −33.54, CRWV −2.61, HUT −17.61.
• The September 6 entry map at 30 days. 11 of 16 calls finished ahead of SPY; CEG, IREN, SNDK, VRT and WDC trailed. Most are unscored watch calls, so this describes where the levels sat, not a grade.

Wrong, or let lapse:

• Okta, above. Both wrong July passes were on names already far up their runs: Okta ("RSI 78 and 3% off its high is chasing") at +44.47, and AXT at +35.30.
• AXT. Its October 1 review date is twelve days gone with no review, the second autopsy to say so. The reopen condition ("bases above its 200-day (~$42.55) for a full quarter AND revenue…") has never been evaluated, and the price now sits on its 200-day, the first week the condition is even testable.
• Zscaler, above. A met, written condition declined in prose.
• Argenx. The October 5 flagship called it "the cleanest dip on the list". Three days later the Sjögren's trial halt (Endpoints News, October 8) took it under its 200-day, the June 29 deep dive's own invalidation fired, and the October 12 deep dive stands aside.
• The July 8 buy cohort at 90 days. Two of eight finished ahead of SPY (NBIS +10.90, TER +17.88); LASR −36.30, KGS −24.52 and CRDO −19.16 led the losers. CGNX, LASR and TER resolved as hits earlier, so their 90-day grades run past the exit.
• Call lifecycles. 53 of 80 open desk calls are past their review dates (54 of 80 on October 2). The one review date inside the week (UMAC, October 9) lapsed. 18 open calls carry an invalidation flag, CBRS and AGIO verified on October 12, and still read open.
• Moving pivots. Microsoft's base pivot read $522.85 on October 5, $535.69 on October 9 and $537.22 on October 12, so each "close through the pivot" was judged against a different line. A level recomputed nightly is not a pre-registered trigger.

What the books did versus what the research said

The research said set levels and don't chase; the books did not chase. Fills, from the paper ledgers and session logs:

• October 5 noon: swing-kid's photonics basket LAZR bought at $48.13; claude-trader's Schlumberger exit at $50.335 (−$38.15); buffer-trader's October BOCT rung.
• October 5 and 7: bench-signals' +20% targets on TTMI ($133.14, +20.4%) and TLN ($378.32, +20.3%).
• October 8: LAZR opened under its stop the day AI hardware sold; the exit check sold it at the $44.50 close (−7.5%).
• October 9: the exit engine sold claude-trader's Bunge at $102.73 (−13.78%), on the book's own October 2 line. Eleven Tier B books held sessions on the close and none bought (Friday report card).
• October 12 noon: claude-trader's Nutrien sale filled, 67.577349 shares at $67.76. swing-kid's SKYY buy was rejected for want of an exact 12:00 ET candle (October 12 EOD record) and stays parked. degen proposed TQQQ and SPXL under Evolved Rule 2, parked for the Tuesday noon fill; no fill is on file at writing.

Six findings:

1. The index book's gate question got answered; the three parked mandate questions did not. degen passed box ENTERs on TQQQ and SPXL five nights running (October 5–9) because no artifact argued for owning the index, the October 5 note's finding 3. On October 9 the coordinator adopted Evolved Rule 2 under the user's delegation ("your call lol but that's degen right??"): the market read admits an index ENTER unless it argues against owning the index, re-graded after four admitted fills or on November 6. The first admissions came October 12, the night the brief said "nothing to buy", two days before the scheduled CPI. TQQQ's box price went from $83.12 (October 5) to $79.61 (October 12) across the passes; degen's own read is "That proves nothing either way." The SOXX-or-SMH question, mention-scalper's Friday rule (four Fridays now) and value-vulture's Rule 2 calculator all remain open. SOXL is moot this week: both semiconductor funds fail Rules 1–2.
2. A pre-written line lived in prose, for the third time. claude-trader's September 28 Nutrien profile wrote "Out" on a close below the 200-day. On October 2 the book held on Exit Rule 6 "without consulting the profile's Out condition" (its own correction, October 9). The exit came three closes deep and filled October 12: the Schlumberger lesson from the October 5 note again.
3. The parked SKYY proposal now contradicts its own break line. SKYY closed at $172.51 on October 12, under the $173.15 level the book named as a failed breakout. The rejection was a data miss, not a judgment, and the replay does not re-check a proposal's written break condition before filling.
4. The basket ticket failed fast. The October 5 note credited LAZR with sidestepping single-name stretch; it failed in three sessions. swing-kid's prose Rule 3 saw a doji at the trade's high on October 6, and the coded exhaustion check cannot see candle shape (its open PB3 gap).
5. Two gates earned their keep. momentum-trader's market gate stayed shut a seventeenth session, and three of its five October 2 gate-only refusals (AVT, ARW, AIS) failed inside five sessions. Every name mention-scalper's Friday rule blocked carried a second lock; its cleanest charts (HUM, NVAX) came off the discovery list, which the paper desk refuses, yet its box screens them anyway.
6. Paper ledger integrity. D214 (filed October 10) restated eight historical own-book fills booked at stale closes: realized P&L moved −$734.51 for yolo, −$530.80 for claude-trader and −$223.83 for bench-signals. The fill path already refuses new stale fills.

Defects. Thirteen escape rows were observed October 6–9 (D201–D213): agents caught three, the blind spot check five, human reads three, a fix-lane read one, and the lab promote door caught D204 by refusing to replay on a gap. No closeout gate caught any. D214 reached the paper ledger.

Lessons that repeat

New this week: the cleanest instance yet of the long-trend rule vetoing the user's own entry pattern (Zscaler), on a name whose written target condition was met.

What to decide this week (not filed; the user's call)

Smallest first. None adds a gate.

1. SDGR: own or decline on the September 23 target's terms. It is inside $23–$26 with the $20.50 stop untouched. If owned, restore the README anchors (SDGR, TWST, ABCL) to the campaign's claimed names so the registry matches the campaign.
2. Record the declines where the machines read them: PACB, NAUT and QSI (business quality); KOD (clinical-stage binary); IOVA (no thesis); AVAX-USD and NTSK (down on the year with negative alpha). Put them in this note's single-line verdict, which the screen prints beside any repeat (it does not suppress one), and as dispositions on the commissioning board's tracked-blindside rows so the board can close them.
3. BWET: own it inside the energy-shock campaign or decline it, and answer the tradability question. Fourth week.
4. Security software: commission or decline. Either commission a successor to the closed tech-rotation campaign's cybersecurity leg with a flag-and-retest entry, or decline the lane in writing. Separately, rule on Zscaler: does the long-trend veto override a met, written target condition on a repair name? Okta's 90-day grade and Zscaler's +16.95% since its call are the cost receipts.
5. TXG: write down now what an arm without the gate means (the July rule says no entry), so it resolves as a documented no rather than a sixth carry.
6. Close the lapsed lifecycles: AXT's review (its reopen condition is testable now), Okta's completed pass, and the 18 open calls carrying invalidation flags.
7. The parked mandate questions: mention-scalper's Friday rule and value-vulture's Rule 2 calculator; SOXL's authority is moot while both semiconductor funds fail. New: should mention-scalper's box screen names the paper desk refuses?

Open checks that fell out of this note (task rows to file, not done here):

• energy-to-humanitarian-transmission, an active campaign, has no watch-for field; the five other active campaigns carry no clause the trigger check can parse.
• Base pivots recomputed nightly serve as entry triggers (Microsoft: three pivots in five sessions).
• The parked-proposal replay does not re-check a proposal's own break condition before filling (SKYY).
• miss-screen does not name its stale-skipped movers in text output.
• Correction to the October 5 note: it said the biotech campaign log's last dated entry was 07-07. The newest dated entry is September 6 (Campaign 1); there is still none since.
• The biotech campaign README still carries the "User holdings inside the lane" line flagged October 5 (presence checked; content not read).
• Unread filings: ZS 8-K (October 6), IOVA 8-K (October 5), IMOS 6-K (October 8).

Sources and limits

• Screens (October 12 EOD receipts): miss-screen, trigger-check, stretch-scan, outlier-scan; join logic research/market-engine/cli/synthesis/miss-screen.ts.
• Prices: research/market-engine/data/summaries/*.json, October 12 settled close; table cells are live bindings to those fields.
• Desk reads: the October 5 flagship, October 9 full-scan and October 12 briefs via market-only extracts; the October 6, 7 and 8 market briefs read only above their exit-advisory sections; research/scans/2026-10-09-{cybersec,tech-insider-buys,lazarus-scan,biotech-scan,ai-infrastructure,crypto-scan,retail-scan,monster-scan,monster-discover}.md; research/scans/2026-10-12-{monster-scan,washout-scan}.md.
• Calls, targets, decisions: research/api-data/desk-calls.json (generated 2026-10-13T06:59Z); research/trading/decisions/CALL-FLAGS.json; deno task market -- decision list --since 2026-10-05 (human-actor rows filtered out unread).
• Campaigns and coverage: research/perspectives/ACTIVE.json; research/perspectives/2026-06-04-biotech-capital-cycle/{README,log}.md; research/market-engine/watchlists/{nvidia-open-agent-ecosystem,_securities}.json; research/workflow/COMMISSIONING.md (generated 2026-10-13T06:42Z).
• Cause checks: research/market-engine/data/stocks/<SYM>/news/latest.json for all 19 names plus TXG; research/stock-events/; research/capture/{articles,tweets,filings}/ for October 5–12.
• Books: research/trading/paper/{degen,claude-trader,swing-kid,momentum-trader,mention-scalper,bench-signals,value-vulture,yolo,yolo-insider-probe,dip-buyer,short-seller,buffer-trader}/PLAYBOOK.md, sessions October 5–12; deno task market -- paper history claude-trader; research/trading/paper/_pending/2026-10-1{2,3}/; research/trading/paper/autotrade/runs.jsonl; ops/tasks/TASKS-ALGO.md; the October 12 EOD record (commit 28f6b95709) for the SKYY rejection.
• Engine rows: ops/tasks/TASKS-ENGINE.md (folded verdict, foreign dollar volume, sequential clauses; all open). Defects: DEFECTS.md D201–D214.
• Prior autopsies: 10-05, 09-28.
• Limits: no execution replay, raw OHLC read, company deep dive or news pull; no counterfactual P&L for passed or blocked entries. The four covered and four stale-skipped movers are not printed by the screen; the stale four are an inference from bar dates. Real-money accounts were not read.